Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion type Assertion NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_head.
- NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion wasGeneratedBy ECO_0000203 NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_provenance.
- NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion wasDerivedFrom befree-2016 NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_provenance.
- NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion SIO_000772 17854396 NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_provenance.
- NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion evidence source_evidence_literature NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_provenance.
- NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_assertion description "[BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked drop in thyroperoxidase (29-fold) and pendrin (20-fold) expression and a considerable increase (five-fold) in GLUT-1 expression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP629887.RADUE4sk-iIDGk3gTbG88-G-W7611Uzw7B70CoEnEhlxE130_provenance.